PATENT CLAIM ANALYSIS

Application Number: 16010945
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-05
Patent Classification: ["514", "262100"]

Abstract:
A novel combination comprising a BTK inhibitor, for example: 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one or a pharmaceutically acceptable salt thereof, and an AKT inhibiting compound, for example: N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which BTK inhibition and/or AKT inhibition is beneficial, e.g., cancer.

Claim (Index 15):
A combination according to  claim 1  or of a combination kit according to  claim 5  where the amount of the compound of Structure (I) is an amount selected from 40 mg to 800 mg, and that amount is suitable for administration once per day in one or more doses, and the amount of the compound of Structure (II) is an amount selected from 50 mg to 300 mg, and that amount is suitable for administration once per day.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 94.0
- Lexical Diversity: 1.57746
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14456180', '12907759', '12499005', '11617645', '14405317']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7082943790663121
- 35 USC 102 Novelty (BERT): 0.5349646753683073
- Combined Prediction Score: 0.6909614086965116
- Mean Citation Score: 308.102434
- Max Citation Score: 326.1658
- Similarity Product: 199.3573112955093

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test